Published in J Clin Oncol on August 20, 2005
Pulmonary vascular disease in mice xenografted with human BM progenitors from patients with pulmonary arterial hypertension. Blood (2012) 1.40
Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. Expert Rev Hematol (2009) 1.06
The role and therapeutic potential of endothelial progenitor cells in tumor neovascularization. ScientificWorldJournal (2010) 0.98
Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents. Cancer Res (2009) 0.92
High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis. PLoS One (2010) 0.85
Impaired right ventricular-pulmonary vascular function in myeloproliferative neoplasms. J Heart Lung Transplant (2014) 0.85
Endothelial precursor cells promote angiogenesis in hepatocellular carcinoma. World J Gastroenterol (2012) 0.84
Characterization of discrete subpopulations of progenitor cells in traumatic human extremity wounds. PLoS One (2014) 0.80
Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis. PLoS One (2016) 0.75
Endothelial progenitor cells in hematologic malignancies. Stem Cell Investig (2016) 0.75
Melittin inhibits tumor angiogenesis modulated by endothelial progenitor cells associated with the SDF-1α/CXCR4 signaling pathway in a UMR-106 osteosarcoma xenograft mouse model. Mol Med Rep (2016) 0.75
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med (2012) 10.07
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood (2008) 7.73
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol (2002) 6.92
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology (2006) 2.72
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood (2013) 2.60
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood (2007) 2.53
Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood (2004) 2.52
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood (2007) 2.41
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2007) 2.33
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica (2004) 2.32
Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood (2011) 2.29
Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study. Br J Haematol (2013) 2.28
Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations. Haematologica (2007) 2.23
Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood (2007) 2.09
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood (2008) 2.09
MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore) (2003) 2.05
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood (2011) 1.93
Circulating endothelial progenitor cells in preterm infants with bronchopulmonary dysplasia. Am J Respir Crit Care Med (2009) 1.92
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica (2002) 1.91
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol (2009) 1.88
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood (2009) 1.78
Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood (2003) 1.76
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74
Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol (2011) 1.59
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol (2012) 1.58
Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood (2004) 1.55
Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. Eur Heart J (2007) 1.55
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica (2008) 1.54
Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood (2008) 1.54
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol (2007) 1.52
The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood (2011) 1.50
Clarifying the use of ruxolitinib in patients with myelofibrosis. Oncology (Williston Park) (2013) 1.49
Consensus conference on the management of tumor lysis syndrome. Haematologica (2008) 1.49
Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood (2009) 1.48
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood (2012) 1.48
Defective expression of GPIb/IX/V complex in platelets from patients with May-Hegglin anomaly and Sebastian syndrome. Haematologica (2002) 1.46
EZH2 mutational status predicts poor survival in myelofibrosis. Blood (2011) 1.45
Therapeutic approaches in myelofibrosis. Expert Opin Pharmacother (2011) 1.43
Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood (2006) 1.42
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). Stem Cells (2006) 1.41
A G to C transversion at the last nucleotide of exon 25 of the MYH9 gene results in a missense mutation rather than in a splicing defect. Eur J Med Genet (2010) 1.41
Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica (2007) 1.39
A policy for the disposal of autologous hematopoietic progenitor cells: report from an Italian consensus panel. Transfusion (2014) 1.38
Thrombosis in primary myelofibrosis: incidence and risk factors. Blood (2009) 1.37
Mutations in the 5' UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet (2011) 1.37
Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome). Am J Kidney Dis (2003) 1.36
Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood (2005) 1.35
Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res (2012) 1.35
ANKRD26-related thrombocytopenia and myeloid malignancies. Blood (2013) 1.32
Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol (2004) 1.32
Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells (2008) 1.30
Maternally transmitted severe glucose 6-phosphate dehydrogenase deficiency is an embryonic lethal. EMBO J (2002) 1.30
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol (2010) 1.29
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood (2012) 1.26
Non-muscle myosin heavy chain IIA and IIB interact and co-localize in living cells: relevance for MYH9-related disease. Int J Mol Med (2006) 1.26
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood (2011) 1.26
Vascular endothelial growth factor stimulates endothelial colony forming cells proliferation and tubulogenesis by inducing oscillations in intracellular Ca2+ concentration. Stem Cells (2011) 1.24
Application of a diagnostic algorithm for inherited thrombocytopenias to 46 consecutive patients. Haematologica (2004) 1.23
Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica (2009) 1.23
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica (2010) 1.22
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer (2014) 1.22
Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One (2012) 1.20
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood (2013) 1.19